BioBlocks Forms International Drug Discovery Team, Representing a New Generation Pre-Clinical CRO

SAN DIEGO, CA--(Marketwire - July 31, 2008) - BioBlocks, Inc., leading provider of chemical building blocks and drug discovery chemistry outsourcing, today announced a significant expansion of its international management team, which is focused on capital efficient, results-driven chemistry for lead optimization. The US team, which is closely tied to the latest drug discovery research and technology, will continue to interface closely with a highly trained team of scientists based in Hungary. To ensure seamless integration and continued focus on strong, goal-oriented project management, BioBlocks has added Warren Wade, Ph.D., Director of Medicinal Chemistry, BioBlocks USA, and Katalin Gero, M.A., General Manager of BioBlocks Hungary. These new additions will work closely with Peter Pallai, Ph.D., CEO of BioBlocks USA, and Laszlo Urogdi, Ph.D., Director of Medicinal Chemistry, BioBlocks Hungary. Together, they form a team that is well positioned to meet the needs of pharmaceutical companies who are turning increasingly to contract research organizations (CRO) to minimize overhead and cut costs. By focusing on meeting drug discovery program metrics, and utilizing an integrated international team, BioBlocks represents a new generation of drug discovery CROs which will augment pharmaceutical pipelines with intelligent and cost effective manpower.

Back to news